Ritverc

Ritverc is a biotechnology company focused on the development and commercialization of antiviral therapies, particularly for the treatment of HIV-1 infection. The company's primary product is Ritverc (elsulfavirine), a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) designed to offer improved efficacy and safety profiles compared to earlier treatments. Ritverc operates primarily within the Russian and CIS markets, where its lead compound has received regulatory approval. The company continues to explore long-acting formulations and combinations to enhance patient adherence and treatment outcomes in the infectious disease space.